OPK Opko Health Inc

OPKO Health, Inc. (NASDAQ:OPK) will release operating and financial results for the three months ended September 30, 2016, after the close of the U.S. financial markets on Monday, November 7, 2016. 

OPKO’s senior management will provide a business update and discuss its results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Monday, November 7, 2016.

The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

CONFERENCE CALL & WEBCAST INFORMATION

WHEN: Monday, November 7, 2016, 4:30 p.m. ETDOMESTIC DIAL-IN: (866) 634-2258INTERNATIONAL DIAL-IN: (330) 863-3454PASSCODE: 12830677

For those unable to participate in the conference call or webcast, a replay will be available beginning November 7, 2016 at 7:30 p.m. ET for a period of time. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 12830677.

The replay can also be accessed for a period of time on OPKO’s website at www.opko.com.

About OPKO Health OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the third-largest clinical laboratory in the U.S. with a core genetic testing business and a 420 person sales force to drive growth and sell new products, such as the 4Kscore prostate cancer test and the Claros 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for stage 3-4 CKD patients with secondary hyperparathyroidism and vitamin D insufficiency, and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro and IV formulation PDUFA is January 2017). Our biologics products under development are hGH-CTP, a once weekly human growth hormone for injection (partnered with Pfizer), long acting Factor VIIa for hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase 1). OPKO has production and distribution assets in several countries abroad, strategic investments and an active business development strategy. More information is available at www.opko.com.

OPKO Health, Inc.Company 305-575-4100 Investor Relations or Media Rooney Partners Terry Rooney, 212-223-0689trooney@rooneyco.com or Marion Janic, 212-223-4017mjanic@rooneyco.com or Investors LHA Anne Marie Fields, 212-838-3777afields@lhai.com or Bruce Voss, 310-691-7100 bvoss@lhai.com